Catalyst Pharmaceutical Partners, Inc. Form 4 October 22, 2009

October 22, 20)09									
FORM	4								PPROVAL	-
	Washington, D.C. 20549								3235-0)287
Check this box if no longer subject to Section 16. Form 4 or				SECUI	RITIES			Expires: Estimated burden hou response	average urs per	y 31, 2005 0.5
Form 5 obligations may contin <i>See</i> Instruct 1(b).	ue. Section 17(a) of the I	Public U	Jtility Hol	ding Co		ange Act of 1934, ct of 1935 or Section 1940	on		
(Print or Type Re	sponses)									
1. Name and Add WALLACE N	Person <u>*</u>	Symbol	er Name an		c	5. Relationship of Reporting Person(s) to Issuer				
			Catalys Inc. [C	st Pharma PRX]	ceutical	Partners,	(Check all applicable)			
(Last)				3. Date of Earliest Transaction (Month/Day/Year)			X_ Director 10% Owner Officer (give title Other (specify below) below)			
355 ALHAM 1370	BRA CIRCLE,	SUITE	10/20/2	2009				,		
(Street)			4. If Amendment, Date Original Filed(Month/Day/Year)			 6. Individual or Joint/Group Filing(Check Applicable Line) _X_ Form filed by One Reporting Person Form filed by More than One Reporting 				
CORAL GAE	BLES, FL 3313	4					Form filed by Person	More than One R	eporting	
(City)	(State)	(Zip)	Tab	ole I - Non-J	Derivativ	e Securities	Acquired, Disposed	of, or Beneficia	lly Owned	
	Transaction Date Aonth/Day/Year)	2A. Deemo Execution any (Month/Da	Date, if	3. Transactic Code (Instr. 8)	4. Secur nAcquired Disposed (Instr. 3,	d (A) or d of (D)	5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature Indirect Beneficial Ownershij (Instr. 4)	l
				Code V	Amount	(D) Pric	ce ()			
Reminder: Repor	t on a separate line	e for each cla	ass of sec	urities bene	-	-				
					infor requ	mation co ired to res ays a curr	espond to the colle ntained in this form pond unless the fo rently valid OMB co	n are not rm	SEC 1474 (9-02)	

 Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned

 (e.g., puts, calls, warrants, options, convertible securities)

1. Title of	2.	3. Transaction Date	3A. Deemed	4.	5. Number of	6. Date Exercisable and	7. Title and Amount of
Derivative	Conversion	(Month/Day/Year)	Execution Date, if	Transacti	orDerivative	Expiration Date	Underlying Securities

Edgar Filing: Catalyst Pharmaceutical Partners, Inc. - Form 4

Security (Instr. 3)	or Exercise Price of Derivative Security		any (Month/Day/Year)	Code (Instr. 8	3) .	Securities Acquired or Dispose (D) (Instr. 3, 4 and 5)	(A) ed of	(Month/Day/Year)		(Instr. 3 and 4)	
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Options to purchase common stock	\$ 0.9	10/20/2009		A		30,000		10/20/2009	10/20/2014	Common Stock	30,000

Reporting Owners

Reporting Owner Name / Addre	SS	Relationships							
	Director	10% Owner	Officer	Other					
WALLACE MILTON J 355 ALHAMBRA CIRCLE SUITE 1370 CORAL GABLES, FL 3313	X 4								
Signatures									
/s/ Milton J. Wallace	10/22/2009								
<pre>**Signature of Reporting Person</pre>	Date								

Explanation of Responses:

* If the form is filed by more than one reporting person, *see* Instruction 4(b)(v).

** Intentional misstatements or omissions of facts constitute Federal Criminal Violations. See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, *see* Instruction 6 for procedure. Potential persons who are to respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB number.